Skip to main content
. 2018 Feb 22;315(1):G80–G94. doi: 10.1152/ajpgi.00008.2018

Fig. 9.

Fig. 9.

In vivo treatment with lovastatin delays liver regeneration. A and B: liver/body weight ratio in control animals and subjected to lovastatin treatment after 48 [sham = 3.82 ± 0.15%, partial hepatectomy (PH) 48-h control = 2.6 ± 0.14% and PH 48-h lovastatin = 1.6 ± 0.09%; A] and 120 h (sham = 3.82 ± 0.16%, PH 120 h control = 3.6 ± 0.01% and PH 120 h lovastatin = 3.6 ± 0.08%; B) of 70% partial hepatectomy (n = 5 animals per condition). C: immunohistochemistry images of liver section from control and lovastatin-treated animals 48 h (sham = 9.3 ± 2.5%, PH 48-h control = 35 ± 7%, PH 48-h lovastatin = 20 ± 5%) and 120 h (sham = 9.3 ± 2.5%, PH 120-h control = 13.2 ± 1.6%, PH 120-h lovastatin = 27.4 ± 3.2%) after PH (n = 5 slices per animal and 5 animals per group). PCNA staining in the nucleus (red arrows) allows identification of proliferation cells in each group. Scale bar = 50 μm. Objective lens: ×10. D and E: quantification of PCNA-positive cells in control and lovastatin-treated animals after 48 h (D) and 120 h (E) of partial hepatectomy (n = 5 slices per animals and 5 animals per condition). *P < 0.01, difference between groups was statistically significant; ns, not significant. Data were analyzed by one-way ANOVA followed by Bonferroni posttests.